(Q34515659)

2 August 2017

title

Etrolizumab for ulcerative colitis: the new kid on the block? (English)

1 reference

2 August 2017

1 reference

Jitin Makker

1

1 reference

2 August 2017

Daniel W Hommes

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

25 February 2016

1 reference

Expert Opinion on Biological Therapy

2 August 2017

published in

1 reference

2 August 2017

volume

16

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

567-572

1 reference

Inflammatory bowel disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Medical therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Ulcerative Colitis: Update on Medical Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Clinical use of anti-TNF therapy and increased risk of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Manual therapy and exercise for adhesive capsulitis (frozen shoulder)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

New therapies for inflammatory bowel disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Essential role for CD103 in the T cell-mediated regulation of experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

The role of CD103⁺ dendritic cells in the intestinal mucosal immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Etrolizumab: anti-β7-a novel therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

A family of beta 7 integrins on human mucosal lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Up-regulation of alphaEbeta7, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1158807

10.1517/14712598.2016.1158807

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference